STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for STAAR Surgical Company for the period ended March 29, 1996. The company manufactures and sells intraocular lenses (IOLs) for cataract surgery and related medical devices. As of May 8, 1996, the company had 12,851,343 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $9,529,078 | $7,307,599 |
| Net Income | $1,497,879 | $1,645,969 |
| Gross Profit Margin | 76.1% | 76.0% |
| Operating Income | $2,182,461 | $1,588,012 |
| Cash and Equivalents | $4,018,619 | $3,399,848 |
| Net Cash from Operations | $1,762,432 | $1,686,614 |
| Total Debt (Current + Long Term) | $6,026,576 | N/A |
| Current Ratio | 2.6:1 | 2.9:1 (Dec 1995) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 30.4% year-over-year, driven by expanding international sales in Europe, South Africa, Australia, and continued U.S. market acceptance.
- Profitability: While operating income rose 37.4%, net income decreased 9.0% to $1.5 million. This decline is primarily attributed to a significant increase in the income tax provision (from 0.8% to 8.5% of revenue) due to the recognition of a deferred tax asset related to net operating loss carryforwards.
- Expense Management: Cost of sales as a percentage of revenue improved slightly to 23.9% due to manufacturing efficiencies. Marketing and selling expenses decreased as a percentage of revenue (29.2% vs 30.1%) due to sales volume growth outpacing cost increases.
- Liquidity: Net working capital increased to $16.5 million. The company refinanced its domestic line of credit in March 1996, lowering interest rates and increasing credit availability.
Outlook, Risks, and Management Commentary
- Guidance: Management expects to continue spending approximately 10% of revenues on Research & Development for product development and approvals. The company anticipates continued profitability and believes future cash needs will be met by operations or additional financing if required.
- Tax Status: The company has remaining net operating loss carryforwards for tax purposes and will not pay Federal income taxes until these are utilized.
- Capital Structure: The company holds an investment in a joint venture accounted for under the equity method. Significant capital expenditures were made in the quarter for property, plant, equipment ($1.3M) and patents/licenses ($974k).
Investor Verification Checklist
- Verify the sustainability of the 30.4% revenue growth rate, particularly in international markets.
- Confirm the status of net operating loss carryforwards and the timeline for Federal tax liability.
- Review the terms of the refinanced line of credit and the impact of the lower interest rate on future cash flows.
- Assess the pipeline for new products currently in the development stage to justify continued R&D spending at 10% of revenue.
- Monitor inventory levels, which increased to $10.8 million, to ensure they align with sales velocity.